Clinical Trial Update: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial investigating effects of oral cladribine on remyelination and inflammation in relapsing-remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Cladribine (cladribine)

Snippet

Sponsor: Pontificia Universidade Católica do Rio Grande do Sul | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: UNKNOWN